Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Shares Outstanding (2019 - 2025)

Vivos Therapeutics' Shares Outstanding history spans 7 years, with the latest figure at $9.3 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $9.3 million for Q4 2025, up 57.68% from a year ago — trailing twelve months through Dec 2025 was $9.3 million (up 57.68% YoY), and the annual figure for FY2025 was $9.3 million, up 57.68%.
  • Shares Outstanding for Q4 2025 was $9.3 million at Vivos Therapeutics, up from $8.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $23.0 million in Q3 2021 to a low of $920592.0 in Q4 2021.
  • The 5-year median for Shares Outstanding is $3.1 million (2024), against an average of $6.1 million.
  • The sharpest move saw Shares Outstanding surged 9109.76% in 2021, then plummeted 96.0% in 2022.
  • Year by year, Shares Outstanding stood at $920592.0 in 2021, then changed by 0.0% to $920592.0 in 2022, then soared by 99.21% to $1.8 million in 2023, then surged by 221.15% to $5.9 million in 2024, then surged by 57.68% to $9.3 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $9.3 million, $8.3 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.